Smoking Cessation & Opioid Dependence Treatment Integration

• Status: Completed
• Trial end date: 2017-04-10
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study was to examine the feasibility of integrating a smoking cessation intervention for cigarette smokers enrolled in an outpatient program for opioid dependence. The secondary purpose was to compare treatment effects as a function of phase in the outpatient program: 0-90 days (weekly attendance), 90 days-1 year (biweekly attendance), and more than 1 year (monthly attendance).

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: West Virginia University
• Collaborators: National Institute on Drug Abuse (NIDA); Pfizer
• Treatments: Varenicline

Criteria

Inclusion Criteria:

• enrolled in the Comprehensive Opioid Addiction Treatment (COAT) program

• report smoking >10 cigarettes per day for >1 year

• provide an expired air carbon monoxide (CO) reading of >10 parts/million (ppm)

• report interest in making a quit attempt in the next 1-6 months (Contemplation or Preparation stages via the Stage of Change; Prochaska & Diclemente, 1983)

• willing to try varenicline for smoking cessation

Exclusion Criteria:

• current engagement in any form of tobacco cessation (e.g., pharmacotherapy)

• current use of contraindicated medications (e.g., theophylline, warfarin, insulin)

• Stage of Change category as Precontemplation (no plans to quit), Action (actively trying to quit), or Maintenance (have already quit)

• self-reported seizures in the past year

• untreated cardiovascular disease

• self-report breast-feeding

• pregnancy (verified by urinalysis)

• not within 4 weeks of advancing to the next COAT group